IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-023-44309-5.html
   My bibliography  Save this article

Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial

Author

Listed:
  • Jian-Xian Lin

    (Fujian Medical University Union Hospital
    Fujian Medical University)

  • Yi-Hui Tang

    (Fujian Medical University Union Hospital)

  • Hua-Long Zheng

    (Fujian Medical University Union Hospital
    Fujian Medical University)

  • Kai Ye

    (Second Affiliated Hospital of Fujian Medical University)

  • Jian-Chun Cai

    (Zhongshan Hospital of Xiamen University)

  • Li-Sheng Cai

    (Zhangzhou Municipal Hospital of Fujian Province)

  • Wei Lin

    (The Affiliated Hospital of Putian University)

  • Jian-Wei Xie

    (Fujian Medical University Union Hospital
    Fujian Medical University)

  • Jia-Bin Wang

    (Fujian Medical University Union Hospital
    Fujian Medical University)

  • Jun Lu

    (Fujian Medical University Union Hospital
    Fujian Medical University)

  • Qi-Yue Chen

    (Fujian Medical University Union Hospital
    Fujian Medical University)

  • Long-Long Cao

    (Fujian Medical University Union Hospital
    Fujian Medical University)

  • Chao-Hui Zheng

    (Fujian Medical University Union Hospital
    Fujian Medical University)

  • Ping Li

    (Fujian Medical University Union Hospital
    Fujian Medical University)

  • Chang-Ming Huang

    (Fujian Medical University Union Hospital
    Fujian Medical University)

Abstract

Prospective evidence regarding the combination of programmed cell death (PD)−1 and angiogenesis inhibitors in treating locally advanced gastric cancer (LAGC) is limited. In this multicenter, randomized, phase 2 trial (NCT04195828), patients with gastric adenocarcinoma (clinical T2-4N + M0) were randomly assigned (1:1) to receive neoadjuvant camrelizumab and apatinib combined with nab-paclitaxel plus S-1 (CA-SAP) or chemotherapy SAP alone (SAP) for 3 cycles. The primary endpoint was the major pathological response (MPR), defined as

Suggested Citation

  • Jian-Xian Lin & Yi-Hui Tang & Hua-Long Zheng & Kai Ye & Jian-Chun Cai & Li-Sheng Cai & Wei Lin & Jian-Wei Xie & Jia-Bin Wang & Jun Lu & Qi-Yue Chen & Long-Long Cao & Chao-Hui Zheng & Ping Li & Chang-M, 2024. "Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-023-44309-5
    DOI: 10.1038/s41467-023-44309-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-44309-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-44309-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Song Li & Wenbin Yu & Fei Xie & Haitao Luo & Zhimin Liu & Weiwei Lv & Duanbo Shi & Dexin Yu & Peng Gao & Cheng Chen & Meng Wei & Wenhao Zhou & Jiaqian Wang & Zhikun Zhao & Xin Dai & Qian Xu & Xue Zhan, 2023. "Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jia Wei & Xiaofeng Lu & Qin Liu & Yao Fu & Song Liu & Yang Zhao & Jiawei Zhou & Hui Chen & Meng Wang & Lin Li & Ju Yang & Fangcen Liu & Liming Zheng & Haitao Yin & Yang Yang & Chong Zhou & Ping Zeng &, 2023. "Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial," Nature Communications, Nature, vol. 14(1), pages 1-12, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-023-44309-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.